English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Cardiac allograft vasculopathy (CAV) remains a major cause of morbidity and mortality among long-term heart transplant recipients. There is an unmet need for a non-invasive biomarker of CAV that could obviate the need to perform surveillance coronary angiograms in these patients. Our aim was to evaluate the performance of Donor-derived Cell Free DNA (dd-cfDNA) as a biomarker of CAV.    Methods  We prospectively measured dd-cfDNA levels in all patients undergoing routine coronary angiography &amp;gt;1 year after heart transplant at a single center. Endpoints included the association between dd-cfDNA levels and the presence CAV, according to several prespecified criteria.    Results  We included 94 heart transplant recipients, a median of 10.9 years after transplant. Coronary angiogram revealed CAV 0 , CAV 1 , CAV 2 , and CAV 3  in 61, 19, 14, and 6% of patients, respectively. Comparison of dd-cfDNA levels in patients with CAV 0  and CAV 1–2–3  (primary end-point) did not show significant differences (0.92%, IQR 0.46–2.0 vs. 0.46%, IQR 0.075–1.5,  p  = 0.059), nor did the comparison between patients with stable CAV (no new coronary lesions since previous angiogram,  n  = 77) and progressive CAV ( n  = 17); dd-cfDNA values 0.735% (IQR 0.195–2.0) vs. 0.9% (IQR 0.12–1.8),  p  = 0.76. However, we found an association between NTproBNP levels and CAV degree ( p  = 0.017). Dd-cfDNA levels did not correlate with NTproBNP (ρ = −0.095).    Conclusion  In this study, dd-cfDNA did not perform as a useful biomarker to avoid surveillance coronary angiograms for CAV diagnosis.    Clinical Trial Notation  Potential Role of Donor-derived Cell Free DNA as a Biomarker in Cardiac Allograft Vasculopathy, NCT 04791852.

Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study